Gavin Giovannoni

Statistics

Publications

Citations

4.9K

H-Index

Active since

2006

Affiliations

Queen Mary University of London(Current)

Biogen (United States)

University Hospital of Basel

Charles University

St. Josef-Hospital

Gavin Giovannoni is an author at Queen Mary University of London specializing in multiple sclerosis, multiple sclerosis therapy, and relapsing-remitting multiple sclerosis treatment.

Publications per year

2006–2022

Publications

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

Life Sciences, Immunology, Neurology +11

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Eva Havrdová, Steven Galetta, Michael Hutchinson et al. · The Lancet Neurology · 2009 · 473 citations

Life Sciences, Neurology, Pharmacotherapy +10

The incidence and significance of anti-natalizumab antibodies

Peter A. Calabresi, Gavin Giovannoni, Christian Confavreux et al. · Neurology · 2007 · 333 citations

Pharmacy, Immunology, Neurology +17

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

David H. Miller, Derek Soon, Kryshani Fernando et al. · Neurology · 2007 · 331 citations

Medicine, Neurology, Pharmacotherapy +13

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Ralf Gold, Gavin Giovannoni, Krzysztof Selmaj et al. · The Lancet · 2013 · 287 citations

Life Sciences, Neurology, Pharmacotherapy +9

1–5 of 34